IRADIMED CORPORATION

IRADIMED CORPORATION

IRMDNYSE / NASDAQHealthcareSmall cap

$81.02-$0.24 (-0.3%)

Last close · Data as of Nov 20, 2026

Market cap
$1.2B
P/E
53.2x
EV / EBITDA
41.9x
Revenue
$83.8M
Net margin
26.8%
ROCE
26.5%

-7.4% over the last year

IRADIMED CORPORATION price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-8.2%
3M
-6.5%
6M
-10.4%
1Y
-7.4%
5Y
+107.5%

52-week range

Day change -$0.24 (-0.3%) from $81 to $81 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in IRMD, bought on each weekday since 2021.

News & filings

What IRADIMED filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthReturn on capital employed of 26.5%.

Concerns

No concern stands out for this company on the data on file.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories.

Read moreShow less

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.

Sector
Healthcare
Shares outstanding
12.7M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.2B
P/E
53.2x
P/B
12.6x
EV / EBITDA
41.9x
EV / Sales
13.7x
P/S
14.3x
52-week high
$105.15
52-week low
$76.68

Profitability

Operating margin
31.2%
Net margin
26.8%
EBITDA margin
32.6%
ROE
23.8%
ROCE
26.5%
ROIC
47.7%
ROA
20.7%
Asset turnover
0.77

Growth

Revenue
$83.8M
Revenue growth, 1Y
14.4%
Revenue CAGR, 3Y
16.3%
Net profit growth, 1Y
16.9%
Free cash flow
$16.5M

Solvency

Current ratio
7.98
Debt / Equity
0.00
Debt / Assets
0.00
CFO / Net profit
1.11
Cash / Market cap
4.3%

Where the revenue went

Of every $100 of FY2025 revenue, $27 was left as net income.

IRADIMED CORPORATION income statement flow, FY2025
IRADIMED CORPORATION income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$19.5M
RevenueGross profit$64.3M
Gross profitOperating expenses$38.2M
Gross profitOperating income$26.1M
Operating incomePretax income$26.1M
Interest and other incomePretax income$2.2M
Pretax incomeTax and other$5.9M
Pretax incomeNet income$22.5M

Revenue and net profit

Revenue grew 14.4% in FY2025; net profit is the dashed line.

IRADIMED CORPORATION revenue and net profit by fiscal year
IRADIMED CORPORATION revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$53.3M$12.8M
FY2023$65.6M$17.2M
FY2024$73.2M$19.2M
FY2025$83.8M$22.5M

Cash flows

FY2025: $24.9M from operations, $16.5M free after investment (dashed).

IRADIMED CORPORATION operating and free cash flow by fiscal year
IRADIMED CORPORATION operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$10.0M$8.2M
FY2023$13.5M$5.5M
FY2024$25.6M$16.8M
FY2025$24.9M$16.5M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$83.8M+14.4%1Y
EBITDA
$27.3M+19.9%1Y
Net profit
$22.5M+16.9%1Y
Cash from operations
$24.9M-2.6%1Y
Free cash flow
$16.5M-1.7%1Y
Revenue CAGR, 3Y
16.3%
Net profit CAGR, 3Y
20.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$83.8M$27.3M$22.5M$16.5M23.8%+14.4%+16.9%

Monthly returns

Month-by-month returns of IRMD across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$108.8M
Liabilities$14.2M
Equity$94.6M
Paid-in capital$30.4M
Retained earnings$64.2M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; IRMD highlighted.

P/E against peers

IRMD trades at 53.2x earnings against a peer median of -11.0x.

  1. IRADIMED CORPORATION (this company)53.2x

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
IRADIMED CORPORATIONIRMDthis company$1.2B53.2x12.6x23.8%41.9x
Alphatec Holdings, Inc.ATEC$1.2B—98.1x-1154.3%—
Inspire Medical Systems, Inc.INSP$1.2B8.4x1.6x18.6%14.3x
CareDx, Inc.CDNA$1.2B-55.9x3.9x-7.0%-248.1x
Kestra Medical Technologies, Ltd.KMTS$1.2B-10.5x5.8x-55.4%-10.2x
AMN Healthcare Services, Inc.AMN$1.2B—1.8x-14.9%19.3x
Schrödinger, Inc.SDGR$1.2B-11.5x3.3x-28.4%-6.6x
Wave Life Sciences Ltd.WVE$1.2B—2.3x-39.4%—
Avanos Medical, Inc.AVNS$1.2B—1.5x-9.4%—
Peer median—-11.0x2.8x-21.6%-6.6x

Year-to-date ROI

IRMD since 1 January, against earlier years.

Historical volatility

IRMD's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

IRADIMED CORPORATION operating margin by fiscal year
IRADIMED CORPORATION operating margin by fiscal year
DateOperating margin
FY202229.3%
FY202330.6%
FY202430.0%
FY202531.2%
LineFY2025
Cost of revenueCost Of Revenue$19.5M
Gross profitGross Profit$64.3M
Operating expensesOperating Expense$38.2M
Research and developmentResearch And Development$3.0M
Total expensesTotal Expenses$57.7M
Pretax incomePretax Income$28.4M

Learn while you research

Academy chapters picked for IRADIMED CORPORATION and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 53.2, learn when high multiples are justified.6 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →